Last updated: February 15, 2026
What Is the Current Market Status of NDC 83324-0296?
NDC 83324-0296 is marketed as Xyrem (sodium oxybate), a central nervous system depressant approved for treating narcolepsy with cataplexy and excessive daytime sleepiness (EDS). Its primary indication is narcolepsy. Xyrem is marketed by Jazz Pharmaceuticals since its FDA approval in 2002.
Market penetration remained stable from 2018 to 2022, with annual sales hovering around $1.1 billion to $1.2 billion. The drug's patient base is estimated at roughly 15,000—20,000 users in the U.S., primarily due to the drug’s specialized indication and restricted distribution channel via the Risk Evaluation and Mitigation Strategy (REMS).
What Are the Key Factors Influencing Xyrem’s Market and Price?
Regulatory Environment and Approvals
Xyrem holds FDA approval for narcolepsy but has not received approval for other indications. Its distribution is controlled via the REMS program to mitigate abuse potential, limiting generic competition and maintaining high prices.
Patent and Exclusivity Status
Xyrem's primary patent expired in 2014. However, patents on the formulation and specific methods of use extended exclusivity until 2024. No approved generic versions are available yet, although multiple manufacturers have filed Abbreviated New Drug Applications (ANDAs). The absence of generics keeps the brand's market share high, with list prices remaining elevated.
Competition and Market Share
The main competition came from generics, but their entry has been delayed due to patent litigation, regulatory hurdles, and REMS restrictions. Alternative treatments like sodium oxybate formulations (e.g., JZP-258 by Jazz Pharmaceuticals) have entered the market but have not significantly displaced Xyrem’s market share.
Price Drivers
The list price for Xyrem remains approximately $29,000 for a 30-day supply, with actual patient costs reduced under insurance plans. Despite the high list price, insurance coverage, and REMS restrictions, the net revenue for Jazz Pharmaceuticals sustains.
Patent Expiry and Potential Generic Entry
Patent expiry in 2024 suggests imminent generic entry. Historically, generic entrants lead to price erosion; comparable products have experienced discounts of 60-80% upon entry.
What Are the Price Projections for the Next 12-24 Months?
Short-term Outlook (Next 12 months)
- Generic Entry: Based on filing activity, generic manufacturers intend to launch shortly after patent expiry in 2024.
- Price Erosion: Assuming generic launch occurs by late 2024, initial price drops could reach 50–60% immediately.
- Market Share Shift: Existing branded sales could decline by 30–50% over 12-18 months post-generics, depending on market acceptance and rebates.
Medium-term Outlook (24 months post-generic entry)
- Price Stabilization: Average prices for generics could stabilize at 70–80% below original list prices.
- Market Volume: Total market volume may decline by 50–70% as prescribers switch to generics and alternative therapies.
- Revenue Impact: Jazz Pharmaceuticals' revenues are expected to decrease proportionally, unless they introduce new formulations or indications.
Market Modeling Assumptions
| Scenario |
Market Share of Branded Xyrem |
Price Reduction |
Revenue Impact |
| Conservative |
50% of pre-generic sales |
40% reduction |
40-50% revenue decline |
| Aggressive |
20% of pre-generic sales |
70–80% reduction |
70-80% revenue decline |
Price Projections Summary
| Event |
Year |
Estimated Price (per 30-day supply) |
Notes |
| Pre-generic |
2023 |
~$29,000 |
Stable market, high brand pricing |
| Patent expiry |
2024 |
N/A |
Regulatory approval for generics expected |
| Post-generic market entry |
2025 |
~$5,000–$9,000 |
Expected price drop, depending on competition |
What Are the Risks and Opportunities?
Risks
- Delays in Generic Approval: Patent litigation delays may prolong high prices.
- Regulatory Changes: Stricter REMS or new approvals could influence market dynamics.
- Market Acceptance: Slow adoption of generics or pricing strategies by insurers could distort projections.
Opportunities
- New Indications: Expanding approval for other conditions can sustain revenue.
- Formulation Innovations: Extended-release or alternative delivery could command premium prices.
- Partnerships and Mergers: Collaborations with generic manufacturers might create licensing opportunities.
Key Takeaways
- The current market for NDC 83324-0296 (Xyrem) is stable with high prices driven by patent and REMS restrictions.
- A wave of generic competition is imminent in 2024, likely leading to significant price declines.
- Revenue for the brand could decline by 50–80% within 1–2 years post-generic entry.
- Development of new formulations or expanded indications may offset revenue declines.
- Market entry timing and regulatory actions will heavily influence actual price and revenue trends.
FAQs
1. When will generic versions of Xyrem likely enter the market?
Generic entry is expected after patent expiry in 2024, pending regulatory and patent litigation outcomes.
2. How much could prices decrease after generics launch?
Price reductions of 60–80% are typical, potentially lowering the 30-day supply cost to under $9,000.
3. Will the brand retain any market share post-generic entry?
Yes, if brand strategies like patent extensions or new formulations are successful, some market share could be preserved.
4. What are the main barriers to generic entry?
Patent protections until 2024, REMS restrictions, and legal disputes limit immediate generic approval.
5. Are there alternative treatments for narcolepsy with similar efficacy?
Yes, medications like JZP-258 and other stimulants are alternatives, but Xyrem remains a key therapy due to its efficacy.
Citations:
[1] Jazz Pharmaceuticals’ financial disclosures, 2022.
[2] FDA drug approval archives, 2002, 2024 patent filings.
[3] IQVIA NPA database, 2022.
[4] Market reports on narcolepsy therapies, 2022.
[5] FDA REMS program, available online.
